novartis semaglutide India market sees new moves from Lupin, Zydus, and Sun Pharma Semaglutide Novartis

Reading the writing on the wall and what it may signify, telemarketing companies, pharmacies, and other stakeholders selling GLP-1 products that are not FDA approved should consider this change in tone and action from both FDA and manufacturers in planning for the future, including in preparing to defend ongoing GLP-1 compounding or potentially realigning their compounding capacity for future markets

Low Blood Sugar Blood sugar levels can drop when taking semaglutide, especially when used in combination with other medications

In case of persistent symptoms, immediate medical attention is required

While some epidemiological studies have raised questions about growth hormone and cancer risk, the evidence remains inconclusive after decades of clinical use